COSMOS Pharmaceutical Corporation (3349.T)

9053.0035.00 (-0.39%)

COSMOS Pharmaceutical Corporation (3349.T) stock comprehensive Fundamental Risk Analysis including financial ratios, debt levels, liquidity, and sustainability metrics. Compare against peers/competitors, industry and sector standards.

Low Bankruptcy RiskLow ProfitabilityEfficient OperationsModerate GrowthModerate QualityAdequate Dividend ProfileIndustry Rank: 67.57%Sector Rank: 75.68%

JPX - Healthcare - Medical - Pharmaceuticals | Market Cap: 717.52B | Next Earnings Date: 14 Oct 2025

Day's Range

8935.00 - 9125.00

52-Week Range

6347.00 - 10045.00

Volume

380.0K / 335.9K (Avg.)

P/E Ratio | EPS

23.15 | 391.09

Trending:

3349.T Fundamental Risk Analysis - Compare Against 2127.T

Comparison against 2127.T

None 3391.T 3141.T 3088.T 2127.T 9843.T

Gauges a company's financial stability and solvency. Value investors pay close attention to leverage and liquidity risk, ensuring the company has enough cushion to withstand downturns without impairing shareholder value.

Debt-to-Equity Ratio

0.05

Increased from previous period

D/E of 0.05 while 2127.T has all-equity financing. Bruce Berkowitz would demand higher returns to justify our leverage.

Net Debt-to-EBITDA

-2.18

Increased from previous period

Both companies show net cash positions. Charlie Munger would investigate if industry economics justify such conservative capitalization.

Interest Coverage Ratio

658.25

Increased from previous period

Coverage exceeding 1.5x 2127.T's 376.02. Charlie Munger would verify if this advantage provides reinvestment flexibility.

Current Ratio

0.71

Decreased from previous period

Current ratio below 50% of 2127.T's 6.64. Jim Chanos would check for potential working capital crisis.

Intangibles-to-Total-Assets Ratio

0.12%

Decreased from previous period

Intangibles less than half of 2127.T's 0.39%. Mohnish Pabrai would verify if this conservative approach sacrifices brand value opportunities.

Select Chart Metric:

3349.T Fundamental Risk Analysis - Compare Against 2127.T

Comparison against 2127.T

None 3391.T 3141.T 3088.T 2127.T 9843.T

Debt-to-Equity Ratio

0.05

Increased from previous period

D/E of 0.05 while 2127.T has all-equity financing. Bruce Berkowitz would demand higher returns to justify our leverage.

Net Debt-to-EBITDA

-2.18

Increased from previous period

Both companies show net cash positions. Charlie Munger would investigate if industry economics justify such conservative capitalization.

Interest Coverage Ratio

658.25

Increased from previous period

Coverage exceeding 1.5x 2127.T's 376.02. Charlie Munger would verify if this advantage provides reinvestment flexibility.

Current Ratio

0.71

Decreased from previous period

Current ratio below 50% of 2127.T's 6.64. Jim Chanos would check for potential working capital crisis.

Intangibles-to-Total-Assets Ratio

0.12%

Decreased from previous period

Intangibles less than half of 2127.T's 0.39%. Mohnish Pabrai would verify if this conservative approach sacrifices brand value opportunities.

Select Chart Metric: